Clinical TrialApr 24, 2026, 04:07 PM
Intellia to Report Phase 3 HAELO Clinical Data on April 27
AI Summary
Intellia Therapeutics announced it will report topline clinical data from its global Phase 3 HAELO clinical trial of lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE). This marks the world's first Phase 3 readout for an in vivo CRISPR gene editing candidate. The company will host a webcast on April 27, 2026, at 8:00 a.m. ET to discuss the results.
Key Highlights
- Intellia to report topline Phase 3 HAELO clinical trial data.
- Data concerns lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE).
- Results will be announced on Monday, April 27, 2026.
- Company will host a webcast at 8:00 a.m. ET to discuss the data.